ID: ALA137025

Max Phase: Preclinical

Molecular Formula: C12H11N3O2

Molecular Weight: 229.24

Molecule Type: Small molecule

Associated Items:

Representations

Canonical SMILES:  O=C1C=C(N2CC2)C(=O)c2c1nc1n2CCC1

Standard InChI:  InChI=1S/C12H11N3O2/c16-8-6-7(14-4-5-14)12(17)11-10(8)13-9-2-1-3-15(9)11/h6H,1-5H2

Standard InChI Key:  RZERNUWWSGYWRV-UHFFFAOYSA-N

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 229.24Molecular Weight (Monoisotopic): 229.0851AlogP: 0.41#Rotatable Bonds: 1
Polar Surface Area: 54.97Molecular Species: NEUTRALHBA: 5HBD: 0
#RO5 Violations: 0HBA (Lipinski): 5HBD (Lipinski): 0#RO5 Violations (Lipinski): 0
CX Acidic pKa: CX Basic pKa: 3.21CX LogP: -0.26CX LogD: -0.26
Aromatic Rings: 1Heavy Atoms: 17QED Weighted: 0.65Np Likeness Score: -0.13

References

1. Zhou R, Skibo EB..  (1996)  Chemistry of the pyrrolo[1,2-alpha]benzimidazole antitumor agents: influence of the 7-substituent on the ability to alkylate DNA and inhibit topoisomerase II.,  39  (21): [PMID:8863809] [10.1021/jm960064d]

Source